Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia

Thrombosis and Haemostasis

Volumn 106, Issue 6, 2011, Pages 1189-1196

  Schouten, Marcel ^a   van't Veer, Cornelis ^a   Roelofs, Joris J T H ^a   Gerlitz, Bruce ^b   Grinnell, Brian W ^b   Levi, Marcel ^a   van der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Animal models; Bacteria; Infectious diseases; Protein C S pathway; Sepsis

Indexed keywords

CHEMOKINE; CYTOKINE; D DIMER; DROTRECOGIN; THROMBIN ANTITHROMBIN COMPLEX;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BLOOD CLOTTING DISORDER; CANCER SURVIVOR; CONTROLLED STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTITHROMBIN III; BIOLOGICAL MARKERS; BLOOD COAGULATION; CYTOKINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; LUNG; MALE; MICE; MICE, INBRED C57BL; PEPTIDE HYDROLASES; PNEUMONIA, PNEUMOCOCCAL; PROTEIN C; RECOMBINANT PROTEINS; STREPTOCOCCUS PNEUMONIAE;

EID: 82555193849     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-06-0438     Document Type: Article

References (42)

1. Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study. Crit Care Med 2005; 33: 952-961.
2. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31: 347-382.
3. Feldman C. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J Lab Clin Med 2004; 143: 269-283.
4. Schouten M, Wiersinga WJ, Levi M, et al. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83: 536-545.
5. Schultz MJ, Millo J, Levi M, et al. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004; 59: 130-135.
6. Rijneveld AW, Weijer S, Bresser P, et al. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34: 1725-1730.
7. Choi G, Schultz MJ, Levi M, et al. Protein C in pneumonia. Thorax 2005; 60: 705-706.
8. Choi G, Hofstra JJ, Roelofs JJ, et al. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 2007; 35: 1362-1368.
9. Rijneveld AW, Florquin S, Bresser P, et al. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003; 102: 934-939.
10. Mosnier LO, Zlokovic BV, Griffin JH, et al. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172.
11. Macias WL, Nelson DR. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004; 32 (Suppl): S223-228.
12. Vail GM, Xie YJ, Haney DJ, et al. Biomarkers of Thrombosis, Fibrinolysis, and Inflammation in Patients with Severe Sepsis due to Community-Acquired Pneumonia with and without Streptococcus pneumoniae. Infection 2009; 37: 358-364.
13. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
14. Schouten M, van't Veer C, van den Boogaard FE, et al. Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia. J Infect Dis 2010; 202: 1600-1607.
15. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377.
16. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005; 33: 2266-2277.
17. Vincent JL, O'Brien J Jr, Wheeler A, et al. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit Care 2006; 10: R74.
18. Schouten M, van 't Veer C, Roelofs JJ, et al. Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study. Crit Care 2010; 14: R145.
19. Berg DT, Gerlitz B, Shang J, et al. Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci USA 2003; 100: 4423-4428.
20. Verheijen JH, Wijngaards G, Kluft C, et al. A Sensitive Spectrophotometric Assay for Extrinsic (Tissue-Type) Plasminogen-Activator - Its Application for Measurements in Plasma. Haemostasis 1982; 12: 62.
21. Verheijen JH, Chang GT, Kluft C. Evidence for the Occurrence of A Fast-Acting Inhibitor for Tissue-Type Plasminogen-Activator in Human-Plasma. Thromb Haemost 1984; 51: 392-395.
22. Rijneveld AW, Levi M, Florquin S, et al. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002; 168: 3507-3511.
23. Knapp S, Wieland CW, Florquin S, et al. Differential roles of CD14 and Toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Am J Respir Crit Care Med 2006; 173: 122-129.
24. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-2100.
25. Taylor FB, Lockhart MS. Whole-Blood Clot Lysis - Invitro Modulation by Activated Protein-C. Thromb Res 1985; 37: 639-649.
26. Suzuki K, Gabazza EC, Hayashi T, et al. Protective role of activated protein C in lung and airway remodeling. Crit Care Med 2004; 32 (Suppl): S262-265.
27. Choi G, Hofstra JJ, Roelofs JJ, et al. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008; 36: 204-210.
28. Van der Poll T, Levi M, Nick JA, et al. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005; 171: 1125-1128.
29. Schouten M, van der Sluijs KF, Gerlitz B, et al. Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study. Crit Care 2010; 14: R65.
30. Macias WL, Dhainaut JF, Yan SCB, et al. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 2002; 72: 391-402.
31. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204: 2439-2448.
32. Mosnier LO, Zampolli A, Kerschen EJ, et al. Hyper-antithrombotic, non-cytoprotective Glu149Ala-activated protein C mutant. Blood 2009; 113: 5970-5978.
33. Gupta A, Gerlitz B, Richardson MA, et al. Distinct Functions of Activated Protein C Differentially Attenuate Acute Kidney Injury. J Am Soc Nephrol 2009; 20: 267-277.
34. Jian MY, Koizumi T, Tsushima K, et al. Activated protein C attenuates acid-aspiration lung injury in rats. Pulm Pharmacol Ther 2005; 18: 291-296.
35. Tanaka A, Minoguchi K, Chen XY, et al. Activated protein C attenuates leukocyte elastase-induced lung injury in mice. Shock 2008; 30: 153-158.
36. Richardson MA, Gupta A, O'Brien LA, et al. Treatment of Sepsis-Induced Acquired Protein C Deficiency Reverses ACE-2 Inhibition and Decreases Pulmonary Inflammatory Response. J Pharmacol Exp Ther 2008; 325: 17-26.
37. Slofstra SH, Groot AP, Maris NA, et al. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol 2006; 149: 740-746.
38. Franscini N, Bachli EB, Blau N, et al. Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation 2004; 110: 2903-2909.
39. Joyce DE, Gelbert L, Ciaccia A, et al. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-11203.
40. Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-1882.
41. Yuda H, Adachi Y, Taguchi O, et al. Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood 2004; 103: 2196-2204.
42. Robriquet L, Collet F, Tournoys A, et al. Intravenous administration of activated protein C in Pseudomonas-induced lung injury in the rat: impact on the lung fluid balance and the inflammatory response. Respir Res 2006; 7: 41.